Krystal Biotech vs Vericel
KRYS and VCEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KRYS and VCEL compare
Krystal Biotech is the larger company, worth 3.0 times as much as Vericel ($9.1B against $3.0B).
On earnings, Krystal Biotech is cheaper: it trades at 41.9× trailing earnings, against 101× for Vericel.
Krystal Biotech grew revenue faster over the last twelve months (26.0% versus 25.3% for Vericel).
Krystal Biotech keeps more of each dollar of sales as profit, with a net margin of 47.9% compared with 10.3% at Vericel.
Vericel scores higher on the StockData Score (16 against 11 for Krystal Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KRYS | VCEL |
|---|---|---|
| Size and price | ||
| Market cap | $9.1B | $3.0B |
| Share price | $308.81 | $59.45 |
| Change, 1 year | 54.8% | 52.5% |
| Change, 5 years | 490% | 34.1% |
| Beta (5Y) | 0.84 | 1.04 |
| Employees | 295 | 398 |
| StockData Score | ||
| Total score | 11 | 16 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 5 (better) |
| Performance score | 3 | 5 (better) |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 41.9× (better) | 101× |
| P/S | 19.4× | 9.4× (better) |
| P/B | 6.4× (better) | 7.9× |
| EV/EBITDA | 36.2× (better) | 70.8× |
| P/FCF | 29.5× (better) | 52.6× |
| FCF yield | 3.4% (better) | 1.9% |
| Fair value | $215.73 | $16.78 |
| Margin of safety | −43.1% (better) | −254% |
| Growth | ||
| Revenue growth (TTM) | 26.0% (better) | 25.3% |
| Revenue growth, 5Y average | – | 17.3% |
| Net income growth (TTM) | 13.2% | 155% (better) |
| EPS growth (TTM) | 10.5% | 211% (better) |
| EPS growth, 5Y average | – | 39.8% |
| Profitability | ||
| Gross margin | – | 74.5% |
| Operating margin | 48.4% (better) | 8.3% |
| Net margin | 47.9% (better) | 10.3% |
| FCF margin | 66.0% (better) | 17.9% |
| Return on equity | 17.5% (better) | 9.4% |
| Return on invested capital | 42.6% (better) | 10.6% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | 42.0× |
| Current ratio | 7.89 (better) | 5.13 |
| Altman Z-score | 38.13 (better) | 14.07 |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.25% |
| Shareholder yield | 0.00% (better) | −0.25% |
| Ownership | ||
| Held by institutions | 102% | 108% |
| Held by insiders | 17.2% | 1.3% |
| Insider net buying, 12 months | −$105M | −$11.0M (better) |
| Short interest, % of float | 12.4% | 10.6% |
Go deeper
- KRYS stock overview
- KRYS income statement
- KRYS valuation and score
- VCEL stock overview
- VCEL income statement
- VCEL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.